Decitabine (NSC 127716)

For research use only. Not for use in humans.

製品コードS1200 別名：Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine, 5-AZA-dC, 5-aza-CdR

CAS No. 2353-33-5

Decitabine (NSC 127716, Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine, 5-AZA-dC, 5-aza-CdR) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.

サイズ

価格(税別)

10mM (1mL in DMSO)	JPY 27700
10mg	JPY 16900
25mg	JPY 30200
50mg	JPY 55100
100mg	JPY 96600

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

代表番号: 03-5615-9297|電子メール：[email protected]|よく尋ねられる質問

文献中Selleckの製品使用例(130)

製品安全説明書

DNA Methyltransferase阻害剤の選択性比較

生物活性

製品説明

ターゲット

DNA methylation ^[1]
(HL-60, KG1a cells)

体外試験

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. ^[1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [³H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. ^[2]

細胞データ

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Eca109	MV7GeY5kfGmxbjDBd5NigQ>?	MnqxNE42yqEQvF2=	MX6yOEBp	M1XzeJdifGW{	MnLxcY9lfWyjdHXzJJRp\SCpZX7lJIV5eHKnc4Ppc44hd2ZiTVHHSU1CKG2nbXLldpM>	M3rtNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUKzNFgzLz5{NUGyN\|A5OjxxYU6=
Eca109	NWnwTXo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTL[pMxNjVxMj61M\|Uh\|ryP	M3PKTVI1NzR6L{eyJIg>	M{n0dZdifGW{	M4e3e4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIgh\G:\|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK=	NHzYWlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGyN\|A5Oid-MkWxNlMxQDJ:L3G+
Eca109	NFT1dIpHfW6ldHnvckBCe3OjeR?=	MkLINE42yqEQvF2=	M4n5dFYwOTJxMkSgbC=>	NFjNPXB4[XSnch?=	NIPJNXZqdmirYnn0d{Bk\WyuIH3p[5JifGmxbtMg	MmHsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkOwPFIoRjJ3MUKzNFgzRC:jPh?=
Eca109	NWOxXGV4TnWwY4Tpc44hSXO\|YYm=	NYWzSmNHOC53wrFOwG0>	MlXsNlQhcA>?	MkXme4F1\XJ?	NHPDWVJqdmirYnn0d{Bk\WyuIHnueoF{cW:w	MlriQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkOwPFIoRjJ3MUKzNFgzRC:jPh?=
Eca109	NWnY[JIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzJdJcxNjYEoN88US=>	NVnX[\|JKOjRiaB?=	MUL3ZZRmeg>?	NUD2coxTcW6mdXPld{BIOi:PIHHydoV{fCCrbjD0bIUh[2WubDDjfYNt\Q>?	NVzFXZpQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlMxQDJpPkK1NVI{ODh{PD;hQi=>
Eca109	MmjGSpVv[3Srb36gRZN{[Xl?	NFTk[mYxNjVxMTFOwG0>	NIK2d3AzPCCq	MYT3ZZRmeg>?	M{TjcYRm[3KnYYPld{BmgHC{ZYPzbY9vKG:oIF7GMe67SjJiYX7kJG1OWDJ?	MoHiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkOwPFIoRjJ3MUKzNFgzRC:jPh?=
SW1116	NYXqZWluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4[xOVAvPS9zL{KvOUDPxE1?	M2izNlQ5KGh?	NUPxVFJYTE2VTx?=	MVHlcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u	M{DXclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe0Nlg3Lz5{NEi3OFI5PjxxYU6=
LOVO	NWK1e\|FCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUW4TmpwOC53L{GvNk82KM7:TR?=	MU[0PEBp	NWTZbZZnTE2VTx?=	MUXlcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
SW1116	M1\YXWZ2dmO2aX;uJGF{e2G7	NHPlUXIyOCEQvF2=	MmDlOFghcA>?	MUnEUXNQ	MlXObY5kemWjc3XzJJRp\SCnZn\lZ5RqfmViYYSgbY5pcWKrdHnu[{BCU1RiYX7kJI1VV1Jic3nncoFtcW6pIIDheIh4[Xm\|IHPvcYJqdmWmIIfpeIgh\2WoaYTpcolj	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
LOVO	M2r2[mZ2dmO2aX;uJGF{e2G7	NXXTU2NbOTBizszN	M1z4flQ5KGh?	M1rKRmROW09?	NU\qWG5vcW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk	NYT6TJAxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O\|QzQDZpPkK0PFc1Ojh4PD;hQi=>
SW1116	M37SV2Fxd3C2b4Ppd{BCe3OjeR?=	M3e0cFExKM7:TR?=	NVvufYREPDhiaB?=	MoDYSG1UVw>?	M3vRZYVvcGGwY3XzJGdm\mm2aX7pZk1qdmS3Y3XkJIFxd3C2b4Ppdy=>	MlTqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{SyPFYoRjJ2OEe0Nlg3RC:jPh?=
LOVO	MmHZRZBweHSxc3nzJGF{e2G7	MniyNVAh\|ryP	MUW0PEBp	NYSwcVlyTE2VTx?=	NWewWGNz\W6qYX7j[ZMhT2WoaYTpcoljNWmwZIXj[YQh[XCxcITvd4l{	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
RPMI-8226	MoSzRZBweHSxc3nzJGF{e2G7	MWWxM\|Ih\|ryP	NYLTT\|JmPDhxN{KvPVYhcA>?	NHG3OVJFVVOR	NYT6OoRPcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	M3rCUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN\|ExQDxxYU6=
OPM-2	NVXzZW9NSXCxcITvd4l{KEG\|c3H5	NGSwUJUyNzJizszN	NHHJXGM4Oi97Nj:xNlAhcA>?	MYXEUXNQ	NVrNTWk2cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	NUKxfFJkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N\|MyODhpPkK0PFM{OTB6PD;hQi=>
JJN3	M{nUVWFxd3C2b4Ppd{BCe3OjeR?=	Mki0NE42NzFizszN	MU[yOE81QCCq	NELmWIZFVVOR	NVvNVZBOcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	NYrKTYU{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N\|MyODhpPkK0PFM{OTB6PD;hQi=>
NCI-H929	NVKzT5ppSXCxcITvd4l{KEG\|c3H5	NGrMdYYyNzJizszN	MUm3Nk86Pi9zMkCgbC=>	MlzmSG1UVw>?	NWnW[3pKcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	M13vOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEOzNVA5Lz5{NEizN\|ExQDxxYU6=
RPMI-8226	NF\mXItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLFNU8zKM7:TR?=	NWnFfVU{OjRxNEivO\|IhcA>?	MWPEUXNQ	Moe4ZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl?	MorQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{OxNFgoRjJ2OEOzNVA5RC:jPh?=
OPM-2	NWjpZohYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nFb\|EwOiEQvF2=	MYiyOE81QC95MjDo	NEXzSXdFVVOR	M1nMNIFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7	Ml;PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{OxNFgoRjJ2OEOzNVA5RC:jPh?=
JJN3	NEDZcHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVewMlUwOSEQvF2=	NF2wbHkzPC92OD:3NkBp	NUPXTnNRTE2VTx?=	MnTKZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl?	Ml\xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{OxNFgoRjJ2OEOzNVA5RC:jPh?=
NCI-H929	MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1G0O\|EwOiEQvF2=	NXvuO5NnOjRxNEivO\|IhcA>?	MX;EUXNQ	MnXaZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl?	NUPIeWFZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N\|MyODhpPkK0PFM{OTB6PD;hQi=>
HeLa	NF;lbnJMcW6jc3WgRZN{[Xl?				NH7zSphMcT1zMECw5qCUPTByMDFOwG0h\m:{IHjFUnQy	NVK0OpptRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFAxQThpPkK0O\|gxODl6PD;hQi=>
HeLa	NV7nbGZrU2mwYYPlJGF{e2G7				Moq3T4k:PS54INMxJFAvPSEQvF2g[o9zKGiHTmSy	NXyweo8yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3PFAxQThpPkK0O\|gxODl6PD;hQi=>
HeLa	NHn4fmxMcW6jc3WgRZN{[Xl?				NIDjfZNMcT1{MT62JOKyKDNwMDFOwG0h\m:{IHjDUnQy	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6MEC5PEc,OjR5OECwPVg9N2F-
HeLa	MUHLbY5ie2ViQYPzZZk>				MVjLbV0yPC52INMxJFQvPiEQvF2g[o9zKGiFTmSz	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd6MEC5PEc,OjR5OECwPVg9N2F-
NB4	NX3pb3l{TnWwY4Tpc44hSXO\|YYm=	NXPOW3Y4Oi53L{WvO{42NzFyIN88US=>	M1vrOFI1KGh?	MWLEUXNQ	NXTHSZdZcW6lcnXhd4ViKHSqZTDlfJBz\XO\|aX;uJI9nKHC{ZXP1dpNweiCvaWKtNVI2[Q>?	NULEdnlURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PFQ5PzBpPkK0OFg1QDdyPD;hQi=>
CD4+ CD25− T	NEfH[GNHfW6ldHnvckBCe3OjeR?=	MlLJNU82KM7:TR?=			M2G5WJJm\HWlZWOg[4xw[mGuIFTORUBu\XSqeXzheIlwdg>?	NInoVXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES3OlM3OCd-MkS0O\|Y{PjB:L3G+
BV-173	MULBdI9xfG:\|aYOgRZN{[Xl?	M4fYWVAvOjVxMD61M\|AvPzVxMTFOwG0>	M4npeFQ5Nzd{L{m2JIg>	MYlCpHBDWw>?	MYDpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:\|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK=	NUjS[GhoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF\|PD;hQi=>
ML-1	NI\IWVJCeG:ydH;zbZMhSXO\|YYm=	NUi1ZWQ5OC5{NT:wMlUwOC55NT:xJO69VQ>?	MmjQOFgwPzJxOU[gbC=>	MX1CpHBDWw>?	NYnmN4JDcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{[xN{c,OjR2MkO2NVM9N2F-
HL-60	M33aNmFxd3C2b4Ppd{BCe3OjeR?=	MUiwMlI2NzBwNT:wMlc2NzFizszN	NXexOJh4PDhxN{KvPVYhcA>?	MmTExsBRSlN?	NHjDcXVqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{[xN{c,OjR2MkO2NVM9N2F-
KG-1a	MlvQRZBweHSxc3nzJGF{e2G7	MoXCNE4zPS9yLkWvNE44PS9zIN88US=>	NYrVZWRGPDhxN{KvPVYhcA>?	NEPHNYjDqFCEUx?=	MUXpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:\|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK=	NXrZe2d4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF\|PD;hQi=>
BV-173	Ml3qSpVv[3Srb36gRZN{[Xl?	M{XPW\|I2OC93MEDuUS=>	M1TxbFQ5KGh?	NE\FZ2LDqFCEUx?=	NE[3O4JqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W=	M4\4N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN\|YyOzxxYU6=
CEM	MXTGeY5kfGmxbjDBd5NigQ>?	NF7rUFUzPTBxNUCwcm0>	NU\pUFhpPDhiaB?=	MVJCpHBDWw>?	NV;mU2IzcW6mdXPld{Bl\WyjeXXkJIFv\CC\|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl	NYDSN3hnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF\|PD;hQi=>
HL-60	NH;PUmxHfW6ldHnvckBCe3OjeR?=	NWjDOoNiOjVyL{WwNI5O	MnO4OFghcA>?	NWT2NlBOyqCSQmO=	NIX0ZVBqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W=	NHy3NGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN\|YyOyd-MkS0NlM3OTN:L3G+
ML-1	NYPZT\|ZCTnWwY4Tpc44hSXO\|YYm=	MnrkNlUxNzVyMH7N	MV:0PEBp	NXfaWmdQyqCSQmO=	NXzPWZNQcW6mdXPld{Bl\WyjeXXkJIFv\CC\|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl	M4X6eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN\|YyOzxxYU6=
DLD-1	NULN[nVHTnWwY4Tpc44hSXO\|YYm=	MX2yOVAwPTBybl2=	MW[0PEBp	MXRCpHBDWw>?	Mmnx[I8hdm:2IHnu[JVk\XNiZHXsZZlm\CCjbnSgd5V{fGGrbnXkJHJQWyCrbnPy[YF{\Q>?	NYKyV21uRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF\|PD;hQi=>
HCT-116	NGHPVnhHfW6ldHnvckBCe3OjeR?=	MW[yOVAwPTBybl2=	M13hPFQ5KGh?	NGLWXHfDqFCEUx?=	NEe4[mVldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{[xN{c,OjR2MkO2NVM9N2F-
U937-A/E-9/14/18	NHfMeo5CeG:ydH;zbZMhSXO\|YYm=	MnLrNE4xOS9yLkGvNU8yOCEQvF2=	NVPEXXN2PDhiaB?=		NX\aVWRWcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NWnG[XRWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNFA1PTZpPkK0N\|AxPDV4PD;hQi=>
HT29	NFywfYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkXMO\|IhcA>?		NXT2ZYo{UUN3ME2xOFAxyrFzN{mg{txO	MoXUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzN{KwOlEoRjJ2MUeyNFYyRC:jPh?=
SW48	NIH6S4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmrnO\|IhcA>?		NVTWbpBNUUN3ME2xOU4zyrF4LkKg{txO	NGX0XWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG3NlA3OSd-MkSxO\|IxPjF:L3G+
HCT116	NWXie3lmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHr0V5k4OiCq		NHn1N2dKSzVyPUGuO:KyOC52IN88US=>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF5MkC2NUc,OjRzN{KwOlE9N2F-
HepG2	NF\zSVhHfW6ldHnvckBCe3OjeR?=	MW[wMlUwOSEQvF2=	M3XJSlI1KGh?	M13wSGROW09?	M{PKSpVxNXKnZ4XsZZRm\CC2aHWgdoVt[XSrdnWgU2NVVjJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w	M4LPVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUS2PFc1Lz5{NEG0Olg4PDxxYU6=
LS174T	MlfZSpVv[3Srb36gRZN{[Xl?	NIPFenAxNjVxMTFOwG0>	M2TwPFI1KGh?	M33CfWROW09?	MYPs[YFlKHSxIHHuJIlv[3KnYYPlJI9nKE:FVF6yJIxmfmWucx?=	M4XNNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUS2PFc1Lz5{NEG0Olg4PDxxYU6=
HepG2	M1ftO2Fxd3C2b4Ppd{BCe3OjeR?=	MnjsNU8yOC9zMECg{txO	NEHPem44KGR?	M3zrbWROW09?	NVT1UphjcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF2Nki3OEc,OjRzNE[4O\|Q9N2F-
LS174T	MX\BdI9xfG:\|aYOgRZN{[Xl?	NIHNSGMyNzFyL{GwNEDPxE1?	MUS3JIQ>	MXzEUXNQ	MlnlbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M3HV[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUS2PFc1Lz5{NEG0Olg4PDxxYU6=
QBC-939	MWrBdI9xfG:\|aYOgRZN{[Xl?	NUW5dHpROS9zMD:xNFAh\|ryP	NIPoU3k4KGR?	MVLEUXNQ	NXHhOXlNcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF2Nki3OEc,OjRzNE[4O\|Q9N2F-
U251	MWfBdI9xfG:\|aYOgRZN{[Xl?	MoKzNU8yOC9zMECg{txO	MV63JIQ>	NET1PHRFVVOR	M{XjTolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MoPlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNE[4O\|QoRjJ2MUS2PFc1RC:jPh?=
HL-60	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XXZ\|Eh\|ryP	Ml7nOFghcA>?		M2GyVIlv[3KnYYPld{BIOi2yaHHz[UBk\WyuIH\yZYN1cW:w	M4jRWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MECwN\|I1Lz5{NECwNFMzPDxxYU6=
MDA‑MB‑453	MVrGeY5kfGmxbjDBd5NigQ>?	MYmwMlIwOSEQvF2=	NVPM[5pvPzJiaB?=		MoXPZ4F2e2W\|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NEKyPEc,OjN6NESyNlg9N2F-
HCC1569	NXrZUGlHTnWwY4Tpc44hSXO\|YYm=	NHP3do8xNjJxMTFOwG0>	NV;vOnRkPzJiaB?=		M2eyfINifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=>	Mm\xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESyNlgoRjJ\|OES0NlI5RC:jPh?=
BT‑474	MWHGeY5kfGmxbjDBd5NigQ>?	NWLne5VrOC5{L{Gg{txO	MYO3NkBp		M4TGO4NifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=>	M1PXRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NlI5Lz5{M{i0OFIzQDxxYU6=
AGS	NHLwUo5CeG:ydH;zbZMhSXO\|YYm=	MVe1M\|ExNzJyL{WwJO69VQ>?	MYK0POKhcMLi	MoHXSG1UVw>?	NVzPXIdQcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6yqB?	M1zRSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUiyO\|g1Lz5{M{W4Nlc5PDxxYU6=
A549	MlnXRZBweHSxc3nzJGF{e2G7	NE\FcmE2NzFyL{KwM\|UxKM7:TR?=	MmexOFjDqGkEoB?=	MX\EUXNQ	MXvpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=>	NX;QSGRHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1PFI4QDRpPkKzOVgzPzh2PD;hQi=>
AGS	M4rGbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TKXFUwOTBxMkCvOVAh\|ryP	M4nxNFQ5yqCqwrC=	MUDEUXNQ	M{PQSIlv\HWlZYOgS\|IwVSCyaHHz[UBienKnc4VCpC=>	NGTCNW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W4Nlc5PCd-MkO1PFI4QDR:L3G+
Kasumi-1	MYPBdI9xfG:\|aYOgRZN{[Xl?	NFi4fogxNjVizszN	Ml23OFjDqGkEoB?=		MYfk[YNz\WG\|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2\|Yx?=	Ml;KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUOzOFgoRjJ\|NEmzN\|Q5RC:jPh?=
OCI-AML3	NY[2O5FpSXCxcITvd4l{KEG\|c3H5	MVSyMlUh\|ryP	MnO1OFjDqGkEoB?=		NVnYO\|NJ\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M>	NWC4RpF{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVM{PDhpPkKzOFk{OzR6PD;hQi=>
MV4-11	NVe3fXdXSXCxcITvd4l{KEG\|c3H5	NEfnbWczNjVizszN	NYfBOZcxPDkEoHlCpC=>		M4nBfoRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj	MkDjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUOzOFgoRjJ\|NEmzN\|Q5RC:jPh?=
NK	M4P5ZWN6fG:2b4jpeJkhSXO\|YYm=	NWXBSHl2OC5yMj2yNEDPxE1?	NX;D[pRQPSCm		MWHk[YNz\WG\|ZYOgeIhmKGO7dH;sfZRq[yCjY4Tpeol1gSCxZjDOT{Bk\WyuczDheEBqdnSncn3l[IlifGViY3;uZ4VvfHKjdHnvcpMhemW\|dXz0bY5oKGmwIHGgWU1{cGGyZXSg[I9{\eLCk4Lld5BwdnOnIHP1dpZm	Mn6xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MkiwPFgoRjJ\|M{K4NFg5RC:jPh?=
NK	NWfHXJBuSXCxcITvd4l{KEG\|c3H5	M{Dlb\|AvODJvMkCg{txO	MW[1JIQ>		M4P0cIRm[3KnYYPlJG5MKGOnbHygdJJwdGmoZYLheIlwdiCjbnSgeoli[mmuaYT5JIF{KHSqZTDjc45k\W62cnH0bY9vKGmwY4LlZZNm\A>?	MoC0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MkiwPFgoRjJ\|M{K4NFg5RC:jPh?=
NK	M2fzeWZ2dmO2aX;uJGF{e2G7	NHjrc4wxNjBzLUKwJO69VQ>?	M3Xxe\|Uh\A>?		NWLHWpVl[2G3c3XzJIh6eG:vZYTofYxifGmxbjDv[kBPUyClZXzsd{BqdiCjIHTvd4XjiJO{ZYPwc45{\Q>?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN{OEC4PEc,OjN\|MkiwPFg9N2F-
MOLT4/DNR	MmHKSpVv[3Srb36gRZN{[Xl?	NFr3S482KM7:TR?=	M37BUVQh\A>?		MlHzdoVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44>	MknUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkC1O\|AoRjJ\|ME[wOVcxRC:jPh?=
Jurkat/DOX	M3PaUmZ2dmO2aX;uJGF{e2G7	M1GwZVUh\|ryP	M{fkPVQh\A>?		MXLy[YR2[2W\|IFHCR2IyKG2UTlGg[ZhxemW\|c3nvci=>	M1;EUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|ME[wOVcxLz5{M{C2NFU4ODxxYU6=
MOLT4/DNR	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVK1JO69VQ>?	NHy1ZXg1KGR?		MVzy[YR2[2W\|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4MEW3NEc,OjNyNkC1O\|A9N2F-
Jurkat/DOX	MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXW1JO69VQ>?	MljWOEBl		MUDy[YR2[2W\|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7	MkG2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkC1O\|AoRjJ\|ME[wOVcxRC:jPh?=
ccRCC	M{H5UmFxd3C2b4Ppd{BCe3OjeR?=	NXLLfm41OC5yMT2xNO69VQ>?	NIq3XWM4OiCq	NX7zV5RsTE2VTx?=	M4e0OIhieyCvaX7pcYFtKGWoZnXjeEBwdiClZXzsJJBzd2yrZnXyZZRqd25?	M1XkOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEK2OFY4Lz5{MkiyOlQ3PzxxYU6=
TNBC	NE\oNVlCeG:ydH;zbZMhSXO\|YYm=	Mnv2NE4xOS1zMN88US=>	MYG3NkBp	M{X3cmROW09?	M{SzNYhieyCvaX7pcYFtKGWoZnXjeEBwdiClZXzsJJBzd2yrZnXyZZRqd25?	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{NkS2O{c,OjJ6Mk[0Olc9N2F-
A498	MnHGRZBweHSxc3nzJGF{e2G7	NV;1SI9XOC5yMT2xNO69VQ>?	NIXzeFk4OiCq	MlX3SG1UVw>?	NH\meFlqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{NkS2O{c,OjJ6Mk[0Olc9N2F-
KIJ265T	NUTMc\|h3SXCxcITvd4l{KEG\|c3H5	NXnZRWZLOC5yMT2xNO69VQ>?	NHX1TVU4OiCq	MkPRSG1UVw>?	NXnNTnp3cW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{NkS2O{c,OjJ6Mk[0Olc9N2F-
MDA-231	M3jP[2Fxd3C2b4Ppd{BCe3OjeR?=	NHXobVUxNjBzLUGw{txO	NYLtRmFNPzJiaB?=	MmnGSG1UVw>?	MmDybY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=>	NIDTVXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyOlQ3Pyd-MkK4NlY1Pjd:L3G+
BT-20	MnTQRZBweHSxc3nzJGF{e2G7	NEjvRlUxNjBzLUGw{txO	MoTjO\|IhcA>?	MlnOSG1UVw>?	MWPpcoR2[2W\|IIP5coVz\2m\|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjh{NkS2O{c,OjJ6Mk[0Olc9N2F-
U937	MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zTcFUuOjBizszN	Mn22NlQwPDhxN{KgbC=>		MYLpcoR2[2W\|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy	NI\leGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke2O\|AzOSd-MkK3OlcxOjF:L3G+
HL60	MkS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXm1MVIxKM7:TR?=	MnHpNlQwPDhxN{KgbC=>		Ml;JbY5lfWOnczDhJIRm[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5JIlvKGFiY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=>	M{H1XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{[3NFIyLz5{Mke2O\|AzOTxxYU6=
U937	NVvv[4g{SXCxcITvd4l{KEG\|c3H5	M2LXN\|E2KM7:TR?=	Mnu4NlQwPDhxN{KgbC=>		MXLpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	NGTvOHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke2O\|AzOSd-MkK3OlcxOjF:L3G+
HL60	NEm5SJRCeG:ydH;zbZMhSXO\|YYm=	M2LuWlE2KM7:TR?=	MmT6NlQwPDhxN{KgbC=>		NHrGOoNqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd4N{CyNUc,OjJ5NkewNlE9N2F-
LS411N	Ml[4RZBweHSxc3nzJGF{e2G7	NWTLUHVpOC53IN88US=>	NXfLdlM4PzJiaB?=		MXrpcoNz\WG\|ZYOgSoF{KG2UTlGgcIV3\Wx?	M2DMbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NE[xOlk2Lz5{MkS2NVY6PTxxYU6=
MDA-MB-231	NYraSWR5SXCxcITvd4l{KEG\|c3H5	NHPnT3cyOCEQvF2=	NX3Dc3BOPDhiaB?=		M4LKe5Jm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NGjoR4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUi4O\|Y6Pyd-MkG4PFc3QTd:L3G+
MCF-7	NXvSPJNHSXCxcITvd4l{KEG\|c3H5	M4XCelExKM7:TR?=	MnrsOFghcA>?		NUT4NoRkemWmdXPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	Mn7wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6OEe2PVcoRjJzOEi3Olk4RC:jPh?=
A375	NFLzdnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDwWYcxNjVizszN	M{G2NVEwPS96IHS=		NHHIVoJqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?=	NEfu[os9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe5OlYzOid-MkG3PVY3OjJ:L3G+
SKMEL1	NXj6bY9rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zsVlAvPSEQvF2=	NFLXV4cyNzVxODDk		NXPRW\|Z7cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO=	NHzHW249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe5OlYzOid-MkG3PVY3OjJ:L3G+
SKMEL3	MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEXZbXIxNjVizszN	NXTWT\|ZVOS93L{ig[C=>		MlfBbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd7Nk[yNkc,OjF5OU[2NlI9N2F-
SKMEL28	MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfnfHpwOC53IN88US=>	NIO2VHIyNzVxODDk		MUPpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W\|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>?	NYfRSGNQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3PVY3OjJpPkKxO\|k3PjJ{PD;hQi=>
MeWo	M4nxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PGTVAvPSEQvF2=	NEm5Z3gyNzVxODDk		Mli1bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN?	NFn5OnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe5OlYzOid-MkG3PVY3OjJ:L3G+
B16	NV7tPWFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV:wMlUh\|ryP	M2jLOlEwPS96IHS=		M1rzRYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy\|	M3PGSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{m2OlIzLz5{MUe5OlYzOjxxYU6=
Ly 1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NETFZ2UzPCCq		NGT3dZlKSzVyPUeuN{DPxE1?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Ly 7	MkDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYnFXXFZOjRiaB?=		MkfwTWM2OD1zMD63JO69VQ>?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL6	NVW0Znl6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVuyOEBp		MlT5TWM2OO,:nkKwJO69VQ>?	M1GydVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 10	MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVKyOEBp		Ml\DTWM2OO,:nkKwJO69VQ>?	M2[zPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
RIVA	M{WxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEHSS4czPCCq		NWnVVWlUUUN3MP-8olIxKM7:TR?=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL2	NXK1XYc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYmyOEBp		M3mxTWlEPTExvK6yNEDPxE1?	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Ly 1	NF[x[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFf5ZnU1QCCq		M3f1WGlEPTB;MD6zOEDPxE1?	NILPVnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O\|IxPDl:L3G+
Ly 7	NXzhSW1FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWm0PEBp		NGTSS5ZKSzVyPUCuNFI2KM7:TR?=	NHTUcFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O\|IxPDl:L3G+
Su-DHL6	NIjpVFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH3BVY81QCCq		NV;CVld[UUN3MP-8olIxKM7:TR?=	NYO2PXhIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O\|IxPDlpPkKxO\|czODR7PD;hQi=>
Ly 10	NVPPW2lkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVK5XoVPPDhiaB?=		Ml3ETWM2OD1zLkig{txO	NG\1WW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O\|IxPDl:L3G+
RIVA	MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MV60PEBp		MWjJR\|Ux97zgMkCg{txO	MkHwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Su-DHL2	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYj6eWhZPDhiaB?=		MWDJR\|UxRTF5LkSg{txO	M1T0e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 1	MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFTyN3Y4OiCq		NYCyPZZtUUN3ME2wMlAyKM7:TR?=	NX6xeJBjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O\|IxPDlpPkKxO\|czODR7PD;hQi=>
Ly 7	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWPLdFNZPzJiaB?=		M2OyZWlEPTB;MD6wNVgh\|ryP	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL6	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWT5Z2hYPzJiaB?=		NU\Qcmx1UUN3ME2xMlYh\|ryP	M1fIOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Ly 10	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWfBbZBvPzJiaB?=		Mn;yTWM2OD1zLkKg{txO	NUPGclBzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O\|IxPDlpPkKxO\|czODR7PD;hQi=>
RIVA	NXXoNZVRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{DMWlczKGh?		M4\TfmlEPTExvK6yNEDPxE1?	MnnzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Su-DHL2	NF\xb2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlHqO\|IhcA>?		NE\zTnBKSzVyPUGxMlIh\|ryP	MlXhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
U373-MAGI	M{fq[2FvfGm4aYLhcEBie3OjeR?=	MUGwMlI2KHSxIEigeW0>	MViyJJRwKDd{IHjydy=>		M3;UT2FvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JHZUXi2JIIDz[ZVld3S7cHXkJGhKXi1zIF7MOE0{KGmwZnXjeIVlKGmwIHj1cYFvKFV\|N{OtUWFIUSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gWVUu\2GpIHzleoVtKGG2IECuNlUhfG9iODD1UUBi\nSncjCyJJRwKDd{IHjyd{BjgSCzUFPSJI1mfGixZB?=	MlHQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUeyOlAoRjJ5MUG3NlYxRC:jPh?=
U373-MAGI	NXK1fVBmSW62aY\pdoFtKGG\|c3H5	M4LkUlAvOjVidH:gPEB2VQ>?	NHPjU2IzKHSxIEeyJIhzew>?		M2CwOGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JHZUXi2JIIDz[ZVld3S7cHXkJGhKXi1zIF7MOE0{KGmwZnXjeIVlKGmwIHj1cYFvKFV\|N{OtUWFIUSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6g[4FoKGyndnXsJIF1KDBwMkWgeI8hQCC3TTDh[pRmeiB{IITvJFczKGi{czDifUByWEOUIH3leIhw\A>?	NFHYU5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GxO\|I3OCd-MkexNVczPjB:L3G+

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	Survivin / Bcl-2 / p53 / c-Myc / DNMT1; PubMed: 26384351 Oncotarget HL60/ADR and kasumi-1 cells were lysed after treated with 0, 1, 2, 4μM decitabine for 72h, and antibodies against β-actin was used as loading control of whole cell proteins in western blotting. The expression of DNMT1, c-Myc, P53, Bcl-2 and Survivin were determined in AML cells. p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN; PubMed: 25762617 Oncotarget Effects of decitabine on the expression of survival pathway proteins at the indicated concentrations. phospho-p38 / p38 / phospho-NFκB / NFκB; PubMed: 26617834 Int J Clin Exp Pathol Decitabine suppressed the phosphorylation of p38 and NF-κB. p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; PubMed: 26692933 Am J Transl Res DAC inhibits the activity of JAK/STAT3 signaling pathway in HL-60 cells. A. HL-60 cells were exposed to 0.2-1.0 μM DAC for 48 h. Cell lysates were prepared and subjected to western blot assay for p-STAT3 (Tyr705 and Ser727) and total STAT3 protein. DAC treatment led to the dephosphorylation of STAT3 both at Tyr705 and Ser727, with moderate effect on total STAT3 protein. B. DAC also down-regulated the expression of p-JAK1 and p-JAK2 as well as total JAK1 and JAK2 in HL-60 cells. The protein expression of STAT3 and JAKs was normalized to that of β-actin and results are representative from three independent experiments. E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax; PubMed: 28152502 Oncotarget The protein level of EMT and invasion related proteins E-cadherin, N-cadherin, Snail, MMP-2, MMP-9 and the protein level of the apoptotic-related proteins, BCL-2 and Bax were detected by western blot. β-actin served as a internal control.	26384351 25762617 26617834 26692933 28152502
Immunofluorescence	DNMT1; PubMed: 21303982 Cancer Res Ren-01 cells (low passage number RCC cells) at <40% confluence were treated with decitabine 0.5 μM. DNMT1 was quantified 48 hours later by immuno-fluorescence (green dots). DAPI was used to stain nuclei (blue stain). E-cadherin / MMP-9; PubMed: 28152502 Oncotarget Immunofluorescence microscopy to identify invasion-promoting molecule MMP-9 and EMT-protective molecule E-cadherin in YES-2 and TE13 cells treated with DAC.	21303982 28152502
Growth inhibition assay	Cell viability; PubMed: 26384351 Oncotarget Cells were treated with Decitabine for 72 h. Viability was measured by MTT assay in AML cells and patient samples Different AML cells.	26384351

体内試験

In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. ^[2]

お薦めの試験操作（参考用のみ）

キナーゼ試験：^[1]	- 合併 DNA synthesis assay : The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [³H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
細胞試験： ^[1]	- 合併細胞株： HL-60 and KG1a 濃度： 0-500 nM 反応時間： 96 hours 実験の流れ： For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines. (参考用のみ)
動物試験：^[2]	- 合併動物モデル： KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice. 投薬量： ≤2.5 mg/kg 投与方法： Administered via i.p. (参考用のみ)

参考

溶解度 (25°C)

体外	DMSO	45 mg/mL (197.18 mM)
	Water	10 mg/mL warmed (43.81 mM)
	Ethanol	Insoluble
体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): water 混合させたのち直ちに使用することを推奨します。	10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Decitabine (NSC 127716) SDFをダウンロードする

分子量	228.21
化学式	C₈H₁₂N₄O₄
CAS No.	2353-33-5
Storage	3 years-20°C powder 2 years-80°C in solvent
別名	Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine, 5-AZA-dC, 5-aza-CdR
Smiles	C1C(C(OC1N2C=NC(=NC2=O)N)CO)O

投与溶媒組成計算器(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量

mg/kg

動物平均体重

投与体積（動物毎）

動物数

匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO+ % + % Tween 80+ % ddH₂O

計算リセット

計算結果:

投与溶媒濃度： mg/ml；

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL，注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。）

投与溶媒調製方法：μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

臨床試験 (data from https://clinicaltrials.gov, updated on 2022-01-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04985656	Withdrawn	Drug: Pevonedistat\|Drug: Decitabine\|Drug: Cedazuridine	Myelodysplastic Syndromes (MDS)	Takeda	October 1 2021	Phase 2
NCT04854889	Recruiting	Drug: Decitabine	Refractory Aplastic Anemia	Institute of Hematology & Blood Diseases Hospital	April 22 2021	Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須
*大学・企業名:
*名前:
*電子メール:
*電話番号:
*内容:

よくある質問（FAQ）

質問1：
Is S1200 a racemic mixture or a monomer?
回答：
S1200 is R form

研究分野別

製品類型

Decitabine (NSC 127716)

文献中Selleckの製品使用例(130)

製品安全説明書

DNA Methyltransferase阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Decitabine (NSC 127716) SDFをダウンロードする

投与溶媒組成計算器(クリア溶液)

便利ツール

モル濃度計算器

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

臨床試験 (data from https://clinicaltrials.gov, updated on 2022-01-17)

技術サポート

よくある質問（FAQ）

DNA Methyltransferaseシグナル伝達経路